This systematic review focusing on the targeted therapy era found solid associations between measurable residual disease (MRD) and clinical outcomes in patients with chronic lymphocytic leukemia.

In children with T-lymphoblastic lymphoma, having an MRD status of less than 0.1% may lead to more time without their cancer worsening or coming back. Having less than 0.1% of minimal residual disease ...

ORLANDO -- A conditioning regimen free from total body irradiation (TBI) appeared to be just as effective as standard of care (SoC) in a common type of childhood leukemia, according to a phase II ...

Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia had better MRD statuses after receiving Iclusig, compared with Gleevec. Patients with newly diagnosed Philadelphia ...

This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and ...

Researchers found that the outcomes were excellent for the 178 end of first consolidation measurable residual disease (MRD)-negative patients, regardless of MRD results at later time points. HealthDay ...

Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with allogeneic stem-cell transplantation or favorable-risk CLL treated with chemoimmunotherapy. Treatment ...

The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...

Acute lymphoblastic leukemia (ALL) manifests as a malignant transformation and proliferation of lymphoid progenitor cells in the bone marrow, blood and eventually extramedullary sites. While mostly ...